Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Clinical trial NCT07094464 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07094464
Sponsor: Daihong Liu
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

TP53-mutated MDS and AML Allogeneic Hematopoietic Stem Cell Transplantation

Start date: 2025-06-01
Primary completion: 2027-06-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.